9 nominees · 5 ballot items.
Elect nine directors; ratify Grant Thornton LLP as auditors; approve advisory 'say-on-pay' for 2025 NEO compensation; approve Second Amendment to 2017 Stock Option Plan (increase by 600,000 shares); approve Sixth Amendment to 2003 Outside Directors Stock Plan (increase by 500,000 shares).
Elect nine directors to serve until the next annual meeting and until their successors are elected and qualified.
Ratify the Audit Committee’s appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for fiscal year 2026.
Non-binding, advisory vote to approve the 2025 compensation of the Company's named executive officers as disclosed in the proxy statement.
This advisory 'say-on-pay' proposal asks shareholders to approve the 2025 compensation of the named executive officers as disclosed in the proxy statement. Management frames compensation as a pay-for-performance program combining cash incentive compensation tied to EBITDA, revenue and operational targets (MIPs) with long-term equity option awards to align executives’ interests with long-term shareholder value. The Board and Compensation Committee emphasize that MIPs include minimum EBITDA thresholds before payouts and that equity grants vest over multi-year periods, reflecting an intent to balance short-term operational incentives with long-term retention and value creation. The vote is non-binding, so management will consider but is not legally required to follow the outcome; nevertheless the Board states it will review results in designing future pay. Contextually, the company reported significant net losses in recent years and uses incentive structures tied to EBITDA and other operational metrics to drive improvements; the proxy discloses no performance payouts for 2025, indicating targets were not met. Potential shareholder concerns include the size and structure of equity awards, executive severance and change-in-control protections described elsewhere in the filing, and whether realized pay appropriately reflects realized performance given recent financial results. Management’s recommendation and rationale stress retention, alignment and competitiveness in an industry requiring technical expertise and stability. For an analyst evaluating governance, the advisory nature, the issuance of sizable option pools elsewhere in the proxy, and employment agreements with termination benefits are relevant when assessing alignment and risk of excessive pay for underperformance.
Approve an amendment to increase the number of shares authorized under the 2017 Stock Option Plan by 600,000 shares (from 1,140,000 to 1,740,000).
This management proposal requests shareholder approval to increase the 2017 Stock Option Plan’s share reserve by 600,000 shares, raising the plan ceiling from 1,140,000 to 1,740,000. Management and the Compensation Committee argue the increase is necessary to continue granting stock options to employees and consultants to attract, retain and motivate talent, and they quantify the incremental potential dilution (approximately $6.0 million aggregate fair market value at the record date price, representing ~2.8% of market capitalization on May 28, 2026). The filing provides context on current plan usage: roughly 527,500 options outstanding and only 57,000 shares remaining under the plan pre-amendment, with historical burn rate and overhang metrics that management uses to justify the requested increase and a projected runway of ~4.5 years at historical grant rates. The Board frames the plan as the primary vehicle for long-term incentives and notes that Rule 16b-3 and Nasdaq rules require stockholder approval for the increase to preserve tax and exchange compliance. Key governance considerations for an analyst include the rate of dilution (overhang), how options are priced and vest, whether shares recycled on forfeiture are available, and the relationship between grants and realized performance given recent company financials. The proposal also ties into other governance elements such as employment agreements that contain post-termination acceleration features, which can affect potential option realizations and dilution. The Board recommends a “FOR” vote, citing alignment of employee and shareholder interests and the operational need to maintain an effective long-term incentive program; shareholders should weigh the projected dilution and historic use of awards against the company’s talent retention needs and performance trajectory.
Approve an amendment to increase the number of shares authorized under the 2003 Outside Directors Stock Plan by 500,000 shares (from 1,600,000 to 2,100,000).
This management proposal seeks shareholder approval to add 500,000 shares to the 2003 Outside Directors Stock Plan, increasing the plan’s authorized amount from 1,600,000 to 2,100,000 shares. The Board notes that nearly all previously authorized shares have been issued or reserved (1,536,585), leaving a small remaining pool, and asserts additional shares are needed to continue granting options and stock awards to non-employee directors as part of their compensation. Management quantifies the incremental potential dilution (approximately $5.03 million at the record-date price, ~2.4% of market cap) and presents governance metrics (burn rate, overhang, dilution) to justify the increase. For governance analysis, the amendment raises typical director-compensation questions: whether the size of grants, vesting schedules (now 25% per year), and elections to receive fees in stock are appropriate for aligning outside directors with shareholders without causing excessive dilution. The proposal ties into prior amendments that changed automatic grant sizes, vesting periods, and issuance mechanics; analysts should examine historical issuance patterns and the role of equity in retaining independent directors. The Board recommends approval, arguing the amendment represents a reasonable amount of dilution to sustain the director compensation program; shareholders should balance that argument against share supply, frequency of grants, and overall dilution given concurrent requests for employee equity under Proposal 4.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | MAK CAPITAL ONE LLC | 4.9% | 918,673 | $10M |
| 2 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 4.2% | 777,142 | $8M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 759,435 | $8M |
| 4 | BlackRock, Inc. | 3.3% | 604,983 | $6M |
| 5 | BlackRock, Inc. | 2.5% | 465,856 | $5M |
| 6 | HEARTLAND ADVISORS INC | 2.2% | 400,000 | $4M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.0% | 371,091 | $4M |
| 8 | DIAMOND HILL CAPITAL MANAGEMENT INC | 1.9% | 355,978 | $4M |
| 9 | STATE STREET CORP | 1.8% | 335,547 | $4M |
| 10 | Potomac Capital Management, Inc. | 1.6% | 296,700 | $3M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.